platelet-Rich plasma as a symptom- and disEaSe-modifying Treatment fOR knee ostEoarthritis - the RESTORE trial

niversity of Melbourne0 个研究点目标入组 288 人开始时间: 2017年6月9日最近更新: 2024年4月8日

适应症

试验速览

暂无简介。

•1)aged greater than or equal to 50 years;
•2)knee pain on most days in the last month;
•3)tibiofemoral osteophytes on x-ray; and
•4)A minimum pain score of 4 on an 11-point numeric rating scale for the last week.

•1)Kellgren and Lawrence (KL) grade 1 indicating questionable disease or grade 4 indicating severe disease;
•2)predominant lateral tibiofemoral disease;
•3)Hyaluronic acid injection in past 6 months, corticosteroid injection in past 3 months or autologous blood product in the past;
•4)knee surgery on their most painful knee within past 12 months;
•5)systemic or inflammatory joint disease;
•6)history of crystalline or neuropathic arthropathy;
•7)knee joint replacement or high tibial osteotomy on their most painful knee;
•8)plan for joint surgery in next 12 months;
•9)other muscular, joint or neurological condition affecting lower limb function;
•10)needle phobia;
•11)immunosuppression or acute infective processes;
•12)cancer or other tumour-like lesions;
•13)bleeding disorder or receiving anti-coagulation therapy;
•14)presence of a warm tense joint effusion;
•15)platelet count greater than or equal to 150,000/microlitre;
•16)any other medical condition precluding participation in the study including contraindication to MRI such as pregnancy;
•17)be unwilling to discontinue NSAID and other analgesic usage for knee pain, with the exception of paracetamol for rescue pain relief, from 2 weeks prior to baseline assessment until the 12 month follow up assessment;
•18)Body mass index (BMI) >40kg/m2 because of problems fitting in to the MRI machine knee coil; and
•19)Inability to understand written/spoken English.

发起方

niversity of Melbourne